KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (Diluted Average) (2018 - 2025)

Historic Shares Outstanding (Diluted Average) for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $200.7 million.

  • Esperion Therapeutics' Shares Outstanding (Diluted Average) rose 297.81% to $200.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.7 million, marking a year-over-year increase of 297.81%. This contributed to the annual value of $187.2 million for FY2024, which is 8154.2% up from last year.
  • Esperion Therapeutics' Shares Outstanding (Diluted Average) amounted to $200.7 million in Q3 2025, which was up 297.81% from $197.5 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $200.7 million for Q3 2025, and its period low was $26.0 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $111.8 million, with a median of $103.1 million in 2023.
  • In the last 5 years, Esperion Therapeutics' Shares Outstanding (Diluted Average) crashed by 940.65% in 2021 and then soared by 15630.6% in 2022.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Shares Outstanding (Diluted Average) stood at $28.9 million in 2021, then surged by 129.76% to $66.4 million in 2022, then surged by 55.26% to $103.1 million in 2023, then soared by 81.54% to $187.2 million in 2024, then rose by 7.24% to $200.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $200.7 million in Q3 2025, compared to $197.5 million in Q2 2025 and $196.1 million in Q1 2025.